Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus

Ann Surg Oncol. 2015 Aug;22(8):2799-805. doi: 10.1245/s10434-014-4336-8. Epub 2015 Jan 9.


Background: Pseudomyxoma peritonei (PMP) is a rare locoregional disease characterized by disseminated intraperitoneal mucinous tumors. However, little is known about PMP from urachal neoplasm as a result of its rarity.

Methods: A total of 9 patients with PMP of urachal origin were treated by cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in our institution. All specimens of surgeries were submitted for pathologic examination. Representative slides of tumors and normal urachus were submitted for immunohistochemical staining.

Results: Four patients were men; the median age was 48 years (range 27-65 years). Initial radiologic examination of all patients showed a cystic tumor located between posterior aspect of umbilicus and the dome of urinary bladder, with or without leaking mucin. Complete CRS and HIPEC were performed in all patients. Until the latest follow-up, local recurrence occurred in 1 patient. Other 8 patients had a median disease-free survival of 27.5 months. Primary urachal tumors of 9 cases were all mucinous adenocarcinoma. Six patients had low-grade mucinous carcinoma peritonei, and 3 patients had high-grade mucinous carcinoma peritonei. Signet ring cells were noted in 4 patients. All tumor specimens of 9 patients were diffuse positive for CK-20, CDX-2, MUC-2, and MUC-5AC, and were variant positive for CK-7.

Conclusions: PMP arising from urachus comes from neoplastic cells with development of intestinal-type mucinous neoplasm. It shares a similar pathophysiology as PMP from appendix. CRS including total urethrectomy, partial cystectomy, and peritonectomy plus HIPEC can be considered as a new option of treatment for PMP originating from urachus.

MeSH terms

  • Adenocarcinoma, Mucinous / chemistry
  • Adenocarcinoma, Mucinous / pathology
  • Adenocarcinoma, Mucinous / therapy*
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • CDX2 Transcription Factor
  • Cisplatin / administration & dosage
  • Cytoreduction Surgical Procedures*
  • Disease-Free Survival
  • Female
  • Homeodomain Proteins / analysis
  • Humans
  • Hyperthermia, Induced*
  • Infusions, Parenteral
  • Keratin-20 / analysis
  • Keratin-7 / analysis
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage
  • Mucin 5AC / analysis
  • Mucin-2 / analysis
  • Peritoneal Neoplasms / chemistry
  • Peritoneal Neoplasms / pathology
  • Peritoneal Neoplasms / therapy*
  • Pseudomyxoma Peritonei / metabolism
  • Pseudomyxoma Peritonei / pathology
  • Pseudomyxoma Peritonei / therapy*
  • Trans-Activators / analysis
  • Urachus*


  • CDX2 Transcription Factor
  • Homeodomain Proteins
  • Keratin-20
  • Keratin-7
  • MUC2 protein, human
  • MUC5AC protein, human
  • Mucin 5AC
  • Mucin-2
  • Trans-Activators
  • Mitomycin
  • Cisplatin